28th Annual JPMorgan Healthcare Conference--Exelixis and Nektar Therapeutics.
The JPMorgan Healthcare Conference, held in San Francisco, included presentations by various pharmaceutical companies summarizing their achievements in 2009 and expectations for 2010. This conference report highlights presentations from Exelixis Inc and Nektar Therapeutics. Investigational drugs from Exelixis, including XL-184 (in collaboration with Bristol-Myers Squibb Co), XL-147 and XL-765 (both in collaboration with sanofi-aventis), and from Nektar, including NKTR-118 and NKTR-119 (both now licensed to AstraZeneca plc), NKTR-171, NKTR-181, NKTR-194, NKTR-102, and NKTR-105, are discussed.
Gale
Sophie
S
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. sophie.gale@thomsonreuters.com
Croasdell
Gary
G
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical; D017321:Clinical Trials, Phase I as Topic; D004345:Drug Industry; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D011092:Polyethylene Glycols / Q000737:chemistry; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D005765:Gastrointestinal Agents; D047428:Protein Kinase Inhibitors; D011092:Polyethylene Glycols